# Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

> **NCT06124729** · — · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab Combined With PD-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT06124729
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06124729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06124729, "Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06124729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*